Claims

1. A pharmaceutical combination comprising :
   a. an antibody specifically recognizing CD38, and
   b. at least bortezomib,
   wherein said antibody comprises at least one heavy chain and at least one light chain, wherein said heavy chain comprises an amino acid sequence represented by SEQ ID NO: 66 and/or said heavy chain comprises three sequential complementarity-determining regions having amino acid sequences SEQ ID NOS: 13, 14 (or 81), and 15, and wherein said light chain comprises an amino acid sequence selected from the group of SEQ ID NOS: 62 and 64, and/or said light chain comprises three sequential complementarity-determining regions having amino acid sequences represented by SEQ ID NOS: 16, 17 and 18.

2. The combination of claim 1, wherein said antibody is a chimeric or humanized antibody.

3. A pharmaceutical combination comprising an antibody and at least bortezomib, wherein said antibody consists of:
   - a light chain comprising an amino acid sequence of SEQ ID NO: 62; and
   - a heavy chain comprising an amino acid sequence of SEQ ID NO: 66.

4. The combination according to claim 1 for use in the treatment of cancer, wherein the antitumor efficacy of the combination is from about 11 to about 42% T/C.

5. The combination according to claim 1 for use in the treatment of cancer, wherein the antitumor efficacy of the combination is from about 0 to about 10% T/C.

6. A pharmaceutical combination according to claim 1 for use in the treatment of cancer.

7. The combination of claim 6, wherein said antibody is a chimeric or humanized antibody.

8. The combination according to claims 6 to 7 wherein the antibody specifically recognizing CD38 and bortezomib are to be administered separately.

9. The combination according to claims 6 to 7 wherein the antibody specifically recognizing CD38 and bortezomib are to be administered semi-simultaneously.

10. The combination according to claims 6 to 7 wherein the administration of antibody specifically recognizing CD38 and bortezomib are to be spaced out over a period of time so as to obtain the maximum efficacy of the combination.

11. An article of manufacture comprising:

a) a packaging material

b) a combination of :

(i) an antibody specifically recognizing CD38, and

(ii) at least bortezomib,

wherein said antibody comprises at least one heavy chain and at least one light chain, wherein said heavy chain has an amino acid sequence SEQ ID NO: 66 and said heavy chain comprises three sequential complementarity-determining regions having amino acid sequences SEQ ID NOS: 13, 14 (or 81), and 15, and wherein said light chain amino acid sequence is SEQ ID NOS: 62 or 64, and said light chain comprises three sequential complementarity-determining regions having amino acid sequences SEQ ID NOS: 16, 17 and18 and

c) a label or package insert contained within said packaging material indicting that said combination thereof is effective for treating cancer.

12. The combination according to claims 6 to 10 wherein the cancer is a CD38 expressing cancer.

13. The combination according to claim 12 wherein the CD38 expressing cancer

is a hematological cancer.

14. The combination according to claim 13 wherein the hematological cancer is selected from the group consisting of multiple myeloma, leukemia, acute and chronic lymphocytic leukemia, acute and chronic lymphoblastic leukemia, B-cell lymphoma, T-cell lymphoma, non-Hodgkin lymphoma; acute and chronic myelogenous leukemias, and promyelocytic leukemia.

15. Use of the combination according to any one of claims 1-3 for the manufacture of a medicament for the treatment of cancer.

16. The use according to claim 15 wherein the cancer is a CD38 expressing cancer.

17. The use according to claim 16 wherein the CD38 expressing cancer is a hematological cancer.

18. The use according to claim 17 wherein the hematological cancer is selected from the group consisting of multiple myeloma, leukemia, acute and chronic lymphocytic leukemia, acute and chronic lymphoblastic leukemia, B-cell lymphoma, T-cell lymphoma, non-Hodgkin lymphoma; acute and chronic myelogenous leukemias, and promyelocytic leukemia.

19. Use of an antibody specifically recognizing CD38 in the manufacture of a medicament for the treatment of cancer, wherein said medicament is to be administered in combination with at least bortezomib, wherein said antibody comprises at least one heavy chain and at least one light chain, wherein said heavy chain comprises an amino acid sequence represented by SEQ ID NO: 66 and/or said heavy chain comprises three sequential complementarity-determining regions having amino acid sequences SEQ ID NOS: 13, 14 (or 81), and 15, and wherein said light chain comprises an amino acid sequence selected from the group of SEQ ID NOS: 62 and 64, and/or said light chain comprises three sequential complementarity-determining regions having amino acid sequences represented by SEQ ID NOS: 16, 17 and 18.

20. The use of claim 19, wherein said antibody is a chimeric or humanized antibody.

21. The use according to any one of claims 19-20, wherein said antibody consists of:
- a light chain comprising an amino acid sequence of SEQ ID NO: 62; and
- a heavy chain comprising an amino acid sequence of SEQ ID NO: 66.

22. The use according to any one of claims 19 to 21 wherein the cancer is a CD38 expressing cancer.

23. The use according to claim 22, wherein the CD38 expressing cancer is a hematological cancer.

24. The use according to claim 23 wherein the hematological cancer is selected from the group consisting of multiple myeloma, leukemia, acute and chronic lymphocytic leukemia, acute and chronic lymphoblastic leukemia, B-cell lymphoma, T-cell lymphoma, non-Hodgkin lymphoma; acute and chronic myelogenous leukemias, and promyelocytic leukemia.